Systematic review with metaanalysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis …
A Cholapranee, GS Hazlewood… - Alimentary …, 2017 - Wiley Online Library
Background Mucosal healing is an important therapeutic endpoint in the management of
Crohn's disease (CD) and ulcerative colitis (UC). Limited data exist regarding the …
Crohn's disease (CD) and ulcerative colitis (UC). Limited data exist regarding the …
consensus statements on therapeutic drug monitoring of antitumour necrosis factor therapy in inflammatory bowel diseases
Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving antitumour necrosis factor (TNF) agents can help optimise outcomes …
patients receiving antitumour necrosis factor (TNF) agents can help optimise outcomes …
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
JF Colombel, R Panaccione, P Bossuyt, M Lukas… - The Lancet, 2017 - thelancet.com
Background Biomarkers of intestinal inflammation, such as faecal calprotectin and C-
reactive protein, have been recommended for monitoring patients with Crohn's disease, but …
reactive protein, have been recommended for monitoring patients with Crohn's disease, but …
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised …
S Vermeire, S Schreiber, R Petryka, T Kuehbacher… - The Lancet, 2017 - thelancet.com
Summary Background Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered,
Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and …
Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and …
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
Objective Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being
investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and …
investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and …
Development and validation of the Nancy histological index for UC
A Marchal-Bressenot, J Salleron, C Boulagnon-Rombi… - Gut, 2017 - gut.bmj.com
Objective We developed a validated index for assessing histological disease activity in UC
and established its responsiveness. Methods Two hundred biopsies were scored. The …
and established its responsiveness. Methods Two hundred biopsies were scored. The …
Management strategies to improve outcomes of patients with inflammatory bowel diseases
JF Colombel, N Narula, L Peyrin-Biroulet - Gastroenterology, 2017 - Elsevier
Strategies for management of inflammatory bowel diseases are shifting from simple control
of symptoms toward full control of these diseases (clinical and endoscopic remission), with …
of symptoms toward full control of these diseases (clinical and endoscopic remission), with …
Systematic review with metaanalysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and …
Introduction Crohn's disease (CD) and ulcerative colitis (UC) have a progressive course
leading to hospitalisation and surgery. The ability of existing therapies to alter disease …
leading to hospitalisation and surgery. The ability of existing therapies to alter disease …
Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease
A Buisson, F Gonzalez, F Poullenot… - Inflammatory bowel …, 2017 - academic.oup.com
Background Objective control of intestinal inflammation during inflammatory bowel disease
(IBD) is becoming the main driver for medical treatment. However, the monitoring tools …
(IBD) is becoming the main driver for medical treatment. However, the monitoring tools …
Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes
B Christensen, SB Hanauer, J Erlich, O Kassim… - Clinical …, 2017 - Elsevier
Background & Aims Mucosal healing, determined by histologic analysis, is a potential
therapeutic target for patients with ulcerative colitis (UC). However, the histologic features of …
therapeutic target for patients with ulcerative colitis (UC). However, the histologic features of …